Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVL1115: A Children's Oncology Group phase 1 consortium report.

Conclusions: Trebananib was well tolerated in pediatric patients with recurrent or refractory solid or CNS tumors. RP2D is 30 mg/kg.
PMID: 28751444 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 27, 2017 Category: Cancer & Oncology Authors: Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL, Liu X, Minard CG, Fox E, Weigel BJ, Blaney S Tags: Clin Cancer Res Source Type: research